
    
      To test if prophylactic anti-B-cell therapy (weekly rituximab) given within 60 to 90 days
      after allogeneic transplantation will decrease allogeneic donor B-cell immunity and possibly
      the incidence of chronic graft-vs-host disease (cGvHD).
    
  